Aurora Cannabis Launches Innovative THC Oil Products In Australia To Meet Diverse Patient Needs

Aurora Cannabis Inc. ACB ACB together with MedReleaf Australia, announced on Wednesday an enhanced product range of premium medical cannabis oil in Australia.

The Canadian medical cannabis giant said the new cannabis oils include a variety of cannabinoid ratios to suit diverse patient needs and are now available for physicians to prescribe. The new products allow doctors to tailor treatments more precisely.

The newly launched cannabis oil products include:

• Aurora THC 25 (Sativa) in a 30mL bottle;
• Aurora THC 25 (Indica) in a 30mL bottle;
• Aurora 12.5:12.5 oil in a 30mL bottle;
• Aurora 50:50 oil in a 30mL bottle; and
• Aurora 10:100 oil in a 30mL bottle.

Read Also: Aurora Cannabis Dominates 30% Of Canada’s Medical Marijuana Exports: Will Its Bold International Expansion Pay Off?

Each formulation offers varying cannabinoid ratios to support personalized treatment options for patients.

“We are thrilled to bring this enhanced range of cannabis oil products to the Australian market,” Andre Jerome, executive vice president of global business development at Aurora, said. “Our mission is to offer healthcare providers and their patients a broader selection of treatment options that meet their various medical needs. By expanding our product portfolio, we continue to demonstrate our commitment to advancing patient care through high-quality, science-driven cannabis solutions.”

The new oils are developed and manufactured at Aurora’s Canadian TGA and EU GMP-certified facility.

• Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.

Background

Aurora's acquisition of  MedReleaf Australia earlier this year was a strategic expansion into one of the fastest-growing international markets. In February Aurora acquired the remaining approximately 90% equity interest of Indica Industries Pty Ltd (MedReleaf Australia) that it did not previously own for AUD$50 million. The debut of premium 1.2g resin cartridges in Australia followed.

At the time of acquisition, Aurora said the move was expected to achieve positive free cash flow in calendar 2024, as MedReleaf Australia generated 12-month net revenue of roughly AUD$40 million and was adjusted EBITDA and operating cash flow positive.

Prior to that, the company held a 10% ownership stake in MedReleaf Australia, which made possible the launch of CraftPlant, a new medical cannabis brand for patients in the Australian market in early 2023.

Read Next:

• Aurora Cannabis Earns Coveted GMP Certification For the Australian Market, Here’s What It Means

ACB Price Action

Aurora's shares traded 1.09% lower at $5.43 per share during the pre-market session on Wednesday morning.